Skip to main content
Top
Published in: Molecular and Cellular Pediatrics 1/2023

Open Access 01-12-2023 | Juvenile Rheumatoid Arthritis | Research

A novel serum calprotectin (MRP8/14) particle-enhanced immuno-turbidimetric assay (sCAL turbo) helps to differentiate systemic juvenile idiopathic arthritis from other diseases in routine clinical laboratory settings

Authors: Dirk Foell, Melanie Saers, Carolin Park, Ninna Brix, Mia Glerup, Christoph Kessel, Helmut Wittkowski, Claas Hinze, Lillemor Berntson, Anders Fasth, Charlotte Myrup, Ellen Nordal, Marite Rygg, Henrik Hasle, Birgitte Klug Albertsen, Troels Herlin, Dirk Holzinger, Christian Niederberger, Bernhard Schlüter

Published in: Molecular and Cellular Pediatrics | Issue 1/2023

Login to get access

Abstract

Background

Differential diagnosis in children with signs of unprovoked inflammation can be challenging. In particular, differentiating systemic juvenile idiopathic arthritis (SJIA) from other diagnoses is difficult. We have recently validated the complex of myeloid-related proteins 8/14 (MRP8/14, also known as S100A8/A9 complex or serum calprotectin) as a helpful biomarker supporting the diagnosis of SJIA. The results were subsequently confirmed with a commercial ELISA. However, further optimization of the analytical technology is important to ensure its feasibility for large-scale use in routine laboratory settings.

Methods

To evaluate the accuracy in identifying children with SJIA, the performance of a particle-enhanced immuno-turbidimetric assay for serum calprotectin (sCAL turbo) on an automated laboratory instrument was analyzed. Samples from 615 children were available with the diagnoses SJIA (n = 99), non-systemic JIA (n = 169), infections (n = 51), other inflammatory diseases (n = 126), and acute lymphoblastic leukemia (ALL, n = 147). In addition, samples from 23 healthy controls were included.

Results

The sCAL turbo assay correlated well with the MRP8/14 ELISA used in previous validation studies (r = 0.99, p < 0.001). It could reliably differentiate SJIA from all other diagnoses with significant accuracy (cutoff at 10,500 ng/ml, sensitivity 84%, specificity 94%, ROC area under curve 0.960, p < 0.001).

Conclusions

Serum calprotectin analyses are a helpful tool supporting the diagnosis of SJIA in children with prolonged fever or inflammatory disease. Here, we show that an immuno-turbidimetric assay for detection of serum calprotectin on an automated laboratory instrument can be implemented in clinical laboratory settings to facilitate its use as a diagnostic routine test in clinical practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392PubMed Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392PubMed
2.
go back to reference Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R et al (2019) Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol 46(2):190–197CrossRefPubMed Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R et al (2019) Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol 46(2):190–197CrossRefPubMed
3.
go back to reference Nigrovic PA (2014) Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol 66(6):1405–1413CrossRefPubMed Nigrovic PA (2014) Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol 66(6):1405–1413CrossRefPubMed
4.
go back to reference Kessel C, Hedrich CM, Foell D (2020) Innately adaptive or truly autoimmune: is there something unique about systemic juvenile idiopathic arthritis? Arthritis Rheumatol 72(2):210–219CrossRefPubMed Kessel C, Hedrich CM, Foell D (2020) Innately adaptive or truly autoimmune: is there something unique about systemic juvenile idiopathic arthritis? Arthritis Rheumatol 72(2):210–219CrossRefPubMed
5.
go back to reference Schulert G, Kessel C (2023) Molecular pathways in the pathogenesis of systemic juvenile idiopathic arthritis. Rheum Dis Clin North Am 49(4):895–911 Schulert G, Kessel C (2023) Molecular pathways in the pathogenesis of systemic juvenile idiopathic arthritis. Rheum Dis Clin North Am 49(4):895–911
6.
go back to reference Pardeo M, Rossi MN, PiresMarafon D, Sacco E, Bracaglia C, Passarelli C et al (2021) Early treatment and IL1RN single-nucleotide polymorphisms affect response to anakinra in systemic juvenile idiopathic arthritis. Arthritis Rheumatol 73(6):1053–1061CrossRefPubMed Pardeo M, Rossi MN, PiresMarafon D, Sacco E, Bracaglia C, Passarelli C et al (2021) Early treatment and IL1RN single-nucleotide polymorphisms affect response to anakinra in systemic juvenile idiopathic arthritis. Arthritis Rheumatol 73(6):1053–1061CrossRefPubMed
7.
go back to reference Ter Haar NM, Tak T, Mokry M, Scholman RC, Meerding JM, de Jager W et al (2018) Reversal of sepsis-like features of neutrophils by interleukin-1 blockade in patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheumatol 70(6):943–956CrossRefPubMed Ter Haar NM, Tak T, Mokry M, Scholman RC, Meerding JM, de Jager W et al (2018) Reversal of sepsis-like features of neutrophils by interleukin-1 blockade in patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheumatol 70(6):943–956CrossRefPubMed
8.
go back to reference Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP et al (2019) Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol 71(7):1163–1173CrossRefPubMedPubMedCentral Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP et al (2019) Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol 71(7):1163–1173CrossRefPubMedPubMedCentral
9.
go back to reference Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ et al (2014) Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 66(4):1034–1043CrossRefPubMed Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ et al (2014) Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 66(4):1034–1043CrossRefPubMed
10.
go back to reference Hinze C, Wittkowski H, Lainka E, Haas JP, Kallinich T, Foell D (2022) Characteristics and disease course of patients with systemic juvenile idiopathic arthritis without arthritis in the German AID-NET cohort. Pediatr Rheumatol Online J 20:O02 Hinze C, Wittkowski H, Lainka E, Haas JP, Kallinich T, Foell D (2022) Characteristics and disease course of patients with systemic juvenile idiopathic arthritis without arthritis in the German AID-NET cohort. Pediatr Rheumatol Online J 20:O02
11.
go back to reference Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T et al (2018) Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J 16(1):7CrossRefPubMedPubMedCentral Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T et al (2018) Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J 16(1):7CrossRefPubMedPubMedCentral
12.
go back to reference DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S et al (2012) Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 64(7):1001–1010PubMed DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S et al (2012) Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 64(7):1001–1010PubMed
13.
go back to reference Gohar F, Kessel C, Lavric M, Holzinger D, Foell D (2016) Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks? Arthritis Res Ther 18:163CrossRefPubMedPubMedCentral Gohar F, Kessel C, Lavric M, Holzinger D, Foell D (2016) Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks? Arthritis Res Ther 18:163CrossRefPubMedPubMedCentral
14.
go back to reference Gohar F, McArdle A, Jones M, Callan N, Hernandez B, Kessel C et al (2019) Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. Ann Rheum Dis 78(8):1107–1113CrossRefPubMed Gohar F, McArdle A, Jones M, Callan N, Hernandez B, Kessel C et al (2019) Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. Ann Rheum Dis 78(8):1107–1113CrossRefPubMed
15.
go back to reference Kessel C, Holzinger D, Foell D (2013) Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol 147(3):229–241CrossRefPubMed Kessel C, Holzinger D, Foell D (2013) Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol 147(3):229–241CrossRefPubMed
16.
go back to reference Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D et al (2009) The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60(3):883–891CrossRefPubMed Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D et al (2009) The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60(3):883–891CrossRefPubMed
17.
go back to reference Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D et al (2003) Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 48(9):2622–2626CrossRefPubMed Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D et al (2003) Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 48(9):2622–2626CrossRefPubMed
18.
go back to reference Holzinger D, Foell D, Kessel C (2018) The role of S100 proteins in the pathogenesis and monitoring of autoinflammatory diseases. Mol Cell Pediatr 5(1):7CrossRefPubMedPubMedCentral Holzinger D, Foell D, Kessel C (2018) The role of S100 proteins in the pathogenesis and monitoring of autoinflammatory diseases. Mol Cell Pediatr 5(1):7CrossRefPubMedPubMedCentral
19.
go back to reference Park C, Miranda-Garcia M, Berendes R, Horneff G, Kuemmerle-Deschner J, Ganser G et al (2022) MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. Rheumatology (Oxford) 61(7):3082–3092CrossRefPubMed Park C, Miranda-Garcia M, Berendes R, Horneff G, Kuemmerle-Deschner J, Ganser G et al (2022) MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. Rheumatology (Oxford) 61(7):3082–3092CrossRefPubMed
20.
go back to reference Pardeo M, Vastert SJ, De Benedetti F (2022) It is about time: the first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 61(7):2724–2725CrossRefPubMed Pardeo M, Vastert SJ, De Benedetti F (2022) It is about time: the first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 61(7):2724–2725CrossRefPubMed
21.
go back to reference Brix N, Kessel C, Foell D, Hasle H, Albertsen BK, Bruun NH, et al (2023) Phagocyte-related S100 proteins and cytokines in acute lymphoblastic leukemia and their prognostic value. Leuk Lymphoma 64(5):981–989 Brix N, Kessel C, Foell D, Hasle H, Albertsen BK, Bruun NH, et al (2023) Phagocyte-related S100 proteins and cytokines in acute lymphoblastic leukemia and their prognostic value. Leuk Lymphoma 64(5):981–989
22.
go back to reference Brix N, Glerup M, Foell D, Kessel C, Wittkowski H, Berntson L et al (2023) Inflammatory biomarkers can differentiate acute lymphoblastic leukemia with arthropathy from juvenile idiopathic arthritis better than standard blood tests. J Pediatr 258:113406CrossRefPubMed Brix N, Glerup M, Foell D, Kessel C, Wittkowski H, Berntson L et al (2023) Inflammatory biomarkers can differentiate acute lymphoblastic leukemia with arthropathy from juvenile idiopathic arthritis better than standard blood tests. J Pediatr 258:113406CrossRefPubMed
23.
go back to reference Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K et al (2020) Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based Nordic juvenile idiopathic arthritis cohort. Arthritis Care Res (Hoboken) 72(4):507–516CrossRefPubMed Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K et al (2020) Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based Nordic juvenile idiopathic arthritis cohort. Arthritis Care Res (Hoboken) 72(4):507–516CrossRefPubMed
24.
go back to reference Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW et al (2012) The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71(6):974–980CrossRefPubMed Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW et al (2012) The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71(6):974–980CrossRefPubMed
25.
go back to reference Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J et al (2010) Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303(13):1266–1273CrossRefPubMed Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J et al (2010) Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303(13):1266–1273CrossRefPubMed
26.
go back to reference Shimizu M, Nakagishi Y, Yachie A (2013) Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 61(2):345–348CrossRefPubMed Shimizu M, Nakagishi Y, Yachie A (2013) Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 61(2):345–348CrossRefPubMed
27.
go back to reference Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J et al (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58(12):3924–3931CrossRefPubMedPubMedCentral Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J et al (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58(12):3924–3931CrossRefPubMedPubMedCentral
28.
go back to reference Kessel C, Fall N, Grom A, de Jager W, Vastert S, Strippoli R et al (2021) Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. Lancet Rheumatol 3(8):E563–E573CrossRef Kessel C, Fall N, Grom A, de Jager W, Vastert S, Strippoli R et al (2021) Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. Lancet Rheumatol 3(8):E563–E573CrossRef
Metadata
Title
A novel serum calprotectin (MRP8/14) particle-enhanced immuno-turbidimetric assay (sCAL turbo) helps to differentiate systemic juvenile idiopathic arthritis from other diseases in routine clinical laboratory settings
Authors
Dirk Foell
Melanie Saers
Carolin Park
Ninna Brix
Mia Glerup
Christoph Kessel
Helmut Wittkowski
Claas Hinze
Lillemor Berntson
Anders Fasth
Charlotte Myrup
Ellen Nordal
Marite Rygg
Henrik Hasle
Birgitte Klug Albertsen
Troels Herlin
Dirk Holzinger
Christian Niederberger
Bernhard Schlüter
Publication date
01-12-2023
Publisher
Springer International Publishing
Published in
Molecular and Cellular Pediatrics / Issue 1/2023
Electronic ISSN: 2194-7791
DOI
https://doi.org/10.1186/s40348-023-00168-0

Other articles of this Issue 1/2023

Molecular and Cellular Pediatrics 1/2023 Go to the issue